Treating metastatic pancreatic ductal adenocarcinoma: NALIRIFOX as new standard?

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Access to Document

@article{122c5c513e734a80b827295bca14a906,

title = "Treating metastatic pancreatic ductal adenocarcinoma: NALIRIFOX as new standard?",

author = "Besselink, {Marc G.} and Wilmink, {Johanna W.}",

year = "2023",

month = oct,

day = "7",

doi = "https://doi.org/10.1016/S0140-6736(23)01521-0",

language = "English",

volume = "402",

pages = "1217--1218",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10409",

}

TY - JOUR

T1 - Treating metastatic pancreatic ductal adenocarcinoma

T2 - NALIRIFOX as new standard?

AU - Besselink, Marc G.

AU - Wilmink, Johanna W.

PY - 2023/10/7

Y1 - 2023/10/7

UR - http://www.scopus.com/inward/record.url?scp=85173040259&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/S0140-6736(23)01521-0

DO - https://doi.org/10.1016/S0140-6736(23)01521-0

M3 - Comment/Letter to the editor

C2 - 37708905

SN - 0140-6736

VL - 402

SP - 1217

EP - 1218

JO - The Lancet

JF - The Lancet

IS - 10409

ER -